Trazodone After 65: What Women Need to Know About the Transition from Older-Adult to Ongoing Adult Care

Why Trazodone Use in Women Over 65 Deserves Its Own Conversation

Trazodone is one of the most commonly prescribed drugs for sleep in older adults, yet the clinical guidance written for this drug was built almost entirely on data from mixed-sex or male-dominated trials. For women over 65, the story is meaningfully different.

After menopause, your body composition shifts toward more adipose tissue and less lean mass. Adipose tissue is where trazodone distributes, so the same 50 mg dose can linger longer in a postmenopausal woman than it did in that same woman at 45. Liver CYP3A4 activity, the main enzyme that clears trazodone, declines with age and is further influenced by estrogen withdrawal. The result: standard doses can produce higher-than-expected blood levels, deeper sedation, and a longer window of next-morning impairment.

None of this is obscure pharmacology. It is the reason the American Geriatrics Society Beers Criteria flags all sedating medications in adults over 65 and recommends the lowest effective dose with regular reassessment.

The Evidence Gap Women Should Know About

Women have been historically underrepresented in trazodone clinical trials. Most pharmacokinetic studies that inform geriatric dosing used predominantly male samples, and sex-stratified safety data on fall risk, fracture, and next-day sedation in postmenopausal women specifically is thin. Where data in women exists, this article says so directly. Where it is extrapolated from mixed-sex older-adult cohorts, this article says that too.

What Happens to Trazodone in a Postmenopausal Body

Trazodone is metabolized primarily through CYP3A4 and CYP2D6 pathways. After menopause, several physiological shifts affect how this drug moves through your system.

Body Composition and Distribution

Body fat percentage in women increases by roughly 10 to 15 percentage points between premenopause and postmenopause. Because trazodone is lipophilic, a higher fat-to-lean ratio extends its half-life. The drug's half-life in older adults ranges from 5 to 9 hours, compared to 3 to 6 hours in younger adults. In a woman who takes trazodone at 10 p.m., measurable sedating levels can persist well into the morning commute.

Hepatic Clearance After Menopause

Estrogen upregulates several cytochrome P450 enzymes. When estrogen drops after menopause, CYP3A4 activity falls. A 2003 review in Clinical Pharmacokinetics found that hepatic drug clearance decreases by 20 to 40 percent in older adults overall, with women showing steeper declines in some enzyme subtypes. This is extrapolated data, not a trazodone-specific postmenopausal trial, and that distinction matters.

Renal Function and Protein Binding

Serum albumin drops with age, particularly after 70. Trazodone is approximately 89 to 95 percent protein-bound. Lower albumin means more free (active) drug circulating at any given dose. If you have recently lost weight, had a hospitalization, or have any chronic illness affecting nutrition, your effective trazodone dose is higher than what is written on the label.

Fall Risk and Fracture: The Most Urgent Risk for Women Over 65

This is not a theoretical concern. Women over 65 already carry the highest absolute fracture risk of any demographic group, driven by postmenopausal bone loss, lower baseline muscle mass, and reduced protective reflexes.

A 2014 cohort study published in JAMA Internal Medicine found that use of trazodone and other sedating antidepressants was associated with a 1.7-fold increase in hip fracture risk in older adults, with women comprising the majority of the high-fracture subgroup. A separate Canadian analysis in CMAJ found that any sedating medication started in the first two weeks of use carries the highest fall risk window, regardless of dose.

What Raises Your Personal Risk Higher

Your trazodone fall risk is not uniform. It climbs when:

• You are also taking a benzodiazepine, Z-drug, or opioid (additive CNS depression)
• You have peripheral neuropathy, which is common in postmenopausal women with type 2 diabetes
• You take a diuretic for blood pressure, increasing nighttime bathroom trips
• Your bedroom is not fall-proofed (no grab bars, rugs on the floor, dim lighting)
• You have a DEXA-confirmed T-score below -2.5, meaning established osteoporosis

The Orthostatic Hypotension Problem

Trazodone blocks alpha-1 adrenergic receptors, causing blood pressure to drop when you stand. Orthostatic hypotension affects up to 30 percent of adults over 70. In postmenopausal women who are also on antihypertensives, the risk of a standing-up dizzy spell followed by a fall is clinically significant and should be assessed at every visit.

Trazodone and Bone Health: A Connection Clinicians Often Miss

Most clinicians think about trazodone's fall risk in isolation from bone density. For older women, these two risks compound each other in a way that is underappreciated in practice. Here is a framework WomanRx clinicians use to assess the combined fracture burden in women over 65 on trazodone:

The Trazodone Fracture Risk Stack for Postmenopausal Women

1. Baseline bone density (T-score from most recent DEXA)
2. Postmenopausal duration (each decade without estrogen costs roughly 10 to 15 percent trabecular bone)
3. Sedating medication load (trazodone dose plus any co-prescribed CNS depressants)
4. Neuromuscular status (grip strength, single-leg stand time, gait speed)
5. Environmental factors (home safety, footwear, vision)

If a woman scores high on three or more of these domains, the risk-benefit calculation for continuing trazodone at its current dose warrants explicit re-evaluation, not passive continuation.

Trazodone does not directly cause bone loss the way long-term corticosteroids or proton pump inhibitors might. The fracture risk comes from falls. But in a woman with a T-score of -2.5 who is also on 100 mg of trazodone nightly, one fall is all it takes. The National Osteoporosis Foundation estimates that hip fractures result in death within one year in 20 percent of cases, and women account for 75 percent of hip fractures.

Sleep, Menopause, and Why Women Over 65 End Up on Trazodone in the First Place

Sleep disruption in women over 65 is rarely simple. Hot flashes, nocturia, anxiety, restless legs syndrome, and primary insomnia often overlap. The appeal of trazodone is understandable: it is non-habit-forming (unlike benzodiazepines), it is generic and cheap, and it is often perceived as gentler than other antidepressants.

A 2017 systematic review in Sleep Medicine Reviews found that trazodone increased total sleep time and reduced wakefulness after sleep onset in small trials, though the evidence base was graded as low quality and most studies lasted fewer than 6 weeks. Long-term data in older women specifically does not exist in any meaningful form.

When Menopause Itself Is the Sleep Disruptor

If vasomotor symptoms are driving your insomnia, trazodone addresses the symptom (poor sleep) without touching the cause (estrogen deficiency and its downstream effects on thermoregulation). The Menopause Society 2023 position statement states that hormone therapy remains the most effective treatment for vasomotor symptoms in eligible women under 60 or within 10 years of menopause onset. For women who are not candidates for hormone therapy, cognitive behavioral therapy for insomnia (CBT-I) has the strongest evidence base for long-term sleep improvement and carries zero fall risk.

Restless Legs Syndrome in Older Women

Trazodone can actually worsen restless legs syndrome (RLS) in some patients, a side effect rarely mentioned in primary-care settings. RLS prevalence is higher in women than men and increases with age. If your sleep is worse after starting trazodone, RLS worsening is worth discussing with your clinician before the dose is increased.

Depression in Women Over 65: When Trazodone Is the Right Choice

Trazodone is FDA-approved for major depressive disorder and remains appropriate for older women when SSRIs or SNRIs are not tolerated, when sedation is a desired side effect (in a woman with co-occurring insomnia and depression), or when cost is a limiting factor.

For women in this age group, the American Association for Geriatric Psychiatry recommends starting at 25 to 50 mg at bedtime and titrating slowly, with reassessment of both efficacy and side effects at two and four weeks. The target antidepressant dose (150 to 400 mg daily) is meaningfully higher than the sleep dose and carries proportionally greater sedation and orthostatic risk.

Trazodone vs. SSRIs in Older Women

SSRIs remain first-line for depression in older adults in most guidelines, including the 2023 Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines. But SSRIs carry their own risks in postmenopausal women: they are associated with bone density loss (sertraline and paroxetine in particular), hyponatremia, and QTc prolongation. Trazodone does not carry the same bone-loss signal, though the fall risk partially offsets this advantage.

Pregnancy and Lactation Safety

Trazodone is not appropriate for use during pregnancy unless the clinical benefit clearly outweighs the risk, a determination that must be made with a prescribing clinician.

Pregnancy

Trazodone was classified under the older FDA pregnancy Category C system, meaning animal studies showed adverse fetal effects and adequate human data were absent. Human registry data is limited, with small case series suggesting possible increased risk of preterm birth and neonatal adaptation syndrome (symptoms including jitteriness, poor feeding, and irritability in the newborn). For women over 65, pregnancy is not a clinical consideration. For any woman in the reproductive window who is transitioning care and might be prescribed trazodone, reliable contraception is necessary if the drug is used during the reproductive years.

Lactation

Trazodone passes into breast milk in small amounts. A pharmacokinetic study published in the American Journal of Psychiatry found milk-to-plasma ratios of approximately 0.14, suggesting limited infant exposure. LactMed (NIH) classifies trazodone as probably compatible with breastfeeding with monitoring, though data remains sparse. This section is included for completeness given WomanRx's readership across life stages, but the primary focus of this article is the 65-plus population.

Who This Is Right For and Who Should Reconsider

Women Who May Be Good Candidates

• You have co-occurring insomnia and depression and want a single agent
• SSRIs or SNRIs caused intolerable side effects (sexual dysfunction, nausea, weight change)
• You have no significant orthostatic hypotension at baseline
• You do not take other CNS depressants
• Your DEXA T-score is above -1.0 (normal bone density)
• You have completed a home falls assessment and your environment is safe
• Cognitive behavioral therapy for insomnia has been tried and failed or is inaccessible

Women Who Should Reconsider

• You have a history of falls in the past 12 months
• You have a T-score below -2.5 and are not yet on bone-protective therapy
• You take a benzodiazepine, opioid, or muscle relaxant
• You have orthostatic hypotension documented on clinic measurement
• You have significant hepatic impairment (cirrhosis, active hepatitis)
• You have a history of cardiac arrhythmia (trazodone carries a small QTc prolongation signal)
• Your sleep disruption is driven primarily by hot flashes and you are eligible for hormone therapy

Care Transitions After 65: The Medication Reconciliation Gap

The transition from a specialist (psychiatrist, sleep medicine physician) to a primary-care provider, or from inpatient back to outpatient, is the highest-risk moment for trazodone-related adverse events. Medication reconciliation failures account for up to 46 percent of medication errors at hospital discharge, and CNS-active drugs like trazodone are disproportionately involved.

What Every Care Transition Should Include

At every handoff, your care team should confirm:

• Current trazodone dose and indication (sleep vs. Depression; these require different doses and monitoring)
• All other CNS-active medications (prescribed and over-the-counter, including diphenhydramine and melatonin)
• Blood pressure in sitting and standing positions (orthostatic check)
• Fall history in the past six months
• Most recent DEXA date and result
• Renal function (eGFR), liver function, and serum sodium (hyponatremia risk)
• Functional status (can you get up from a chair without using your arms?)

The "Brown Bag" Review

Bring every pill bottle, every supplement, and every OTC product to your first appointment with a new provider. Trazodone interactions with CYP3A4 inhibitors such as clarithromycin, fluconazole, and grapefruit juice can double plasma trazodone levels. Your new clinician cannot catch these interactions if they do not see the full picture.

Dosing Guidance for Women Over 65

The American Geriatrics Society recommends starting any new sedating medication at the lowest available dose and titrating slowly, with explicit reassessment at 4 to 6 weeks.

For sleep in women over 65:

• Starting dose: 25 mg orally at bedtime
• Titration: increase by 25 mg increments no faster than every 7 to 14 days
• Typical effective sleep dose: 50 to 100 mg; doses above 150 mg for sleep alone are rarely justified
• Maximum dose in older adults: 400 mg daily (antidepressant range only, with careful monitoring)

For depression in women over 65:

• Starting dose: 25 to 50 mg at bedtime
• Target antidepressant dose: 150 to 300 mg daily (divided or at bedtime depending on tolerability)
• Reassessment: at 2 weeks for tolerability, 4 to 6 weeks for efficacy

A 2022 meta-analysis in JAMA Psychiatry found that lower antidepressant doses in older adults (defined as doses below 50 percent of the standard adult maximum) were associated with comparable efficacy and meaningfully fewer adverse events in adults over 65. This is not trazodone-specific data, but it supports the geriatric prescribing principle of "start low, go slow."

Monitoring: What Should Happen at Every Visit

The following monitoring schedule reflects best practice for older women on trazodone and is grounded in AGS Beers Criteria guidance and general geriatric pharmacology principles.

| Visit | What to Check | |---|---| | Baseline | Blood pressure (sitting and standing), eGFR, LFTs, serum sodium, falls history, DEXA if not done in 2 years, ECG if cardiac history | | 2 weeks | Orthostatic blood pressure, side effects, sleep quality or mood response | | 4 to 6 weeks | Reassess efficacy; confirm no new falls; review all co-medications | | Every 6 months | Serum sodium (hyponatremia risk), blood pressure, falls reassessment | | Annually | DEXA if T-score was borderline; full medication review; reassess indication |

Sexual Health Considerations for Women Over 65 on Trazodone

Trazodone has a complicated sexual health profile. In men, it is known to cause priapism. In women, the picture is different and less studied.

Some older case reports and small trials suggest trazodone may actually improve sexual function in women through its serotonin antagonism and possible effects on clitoral blood flow. A small trial published in the Journal of Sex and Marital Therapy found that trazodone at 50 to 150 mg improved subjective arousal in premenopausal women with hypoactive sexual desire disorder. Whether this translates to postmenopausal women with genitourinary syndrome of menopause (GSM) is not known. This is a direct evidence gap, and extrapolation should be made with caution.

Postmenopausal women with HSDD (hypoactive sexual desire disorder) should discuss approved treatments, including flibanserin and bremelanotide, with their clinician rather than relying on trazodone's anecdotal reputation for this indication.

Questions to Ask Your Clinician at Your Next Visit

If you are a woman over 65 transitioning care and trazodone is on your medication list, these are the exact questions worth raising:

• "What is this trazodone prescribed for: sleep, depression, or both, and is that still the right indication for me?"
• "Given my bone density results, should we do a formal falls-risk assessment before continuing this dose?"
• "Are any of my other medications interacting with trazodone through the CYP3A4 pathway?"
• "Is cognitive behavioral therapy for insomnia available to me as an alternative?"
• "When was my serum sodium last checked, and do I need an orthostatic blood pressure measurement today?"

"Medication review at every care transition is not optional for older adults on CNS-active drugs. It is the single most effective intervention we have for preventing iatrogenic harm in this population." , Sarah Chen, WHNP, WomanRx Clinical Team